Oncology Drug Snapshot: Axitinib (Inlyta)

Biotechs Seek Federal Coverage of Fertility Preservation Before Gene Therapy

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Haydar Frangoul, MD, Medical Director of Pediatric Hematology/Oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial

FDA Accepts Mesoblast’s BLA for Remestemcel-L for Steroid-Refractory GvHD

Both companies have received unfavorable opinions from the Office of the Inspector General on the matter.

Silviu Itescu, MBBS, FRACP, chief Executive Officer and Managing Director, Mesoblast

Caribou Biosciences chRDNA Technology Provides a Unique Approach to CRISPR-Based Gene Editing

After 3 tries, Mesoblast finally has a PDUFA date for its MSC therapy.

Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences

Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T

Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences, discussed the company’s platform for genome editing.

Ash Alizadeh, MD, PhD, professor of medicine and member, Stanford Cancer Institute

BlueRock Therapeutics Assessing the Potential of Cell Therapy for Parkinson Disease With Phase 1 Trial for Bemdaneprocel

Of 724 patients treated at the center, the cumulative incidence of secondary hematologic malignancy at 3 years posttreatment was 6.5%.

Around the Helix: Cell and Gene Therapy Company Updates – July 24, 2024

In honor of World Brain Day, observed annually on July 22 by patient and clinician communities, CGTLive is taking a closer look at this ongoing study.

Related Content

Biotechs Seek Federal Coverage of Fertility Preservation Before Gene Therapy

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

FDA Accepts Mesoblast’s BLA for Remestemcel-L for Steroid-Refractory GvHD

Both companies have received unfavorable opinions from the Office of the Inspector General on the matter.

Caribou Biosciences chRDNA Technology Provides a Unique Approach to CRISPR-Based Gene Editing

After 3 tries, Mesoblast finally has a PDUFA date for its MSC therapy.

Stanford Study Finds Low Risk of Secondary Blood Cancers After CAR-T

Steve Kanner, PhD, the chief scientific officer of Caribou Biosciences, discussed the company’s platform for genome editing.

BlueRock Therapeutics Assessing the Potential of Cell Therapy for Parkinson Disease With Phase 1 Trial for Bemdaneprocel

Of 724 patients treated at the center, the cumulative incidence of secondary hematologic malignancy at 3 years posttreatment was 6.5%.